Naslov (srp)

Uticaj biološke i imunosupresivne terapije na markere oštećenja miokarda kod pacijenata obolelih od ulceroznog kolitisa

Autor

Cvetković, Mirjana, 1971-

Doprinosi

Zdravković, Nataša, 1973-
Davidović, Goran, 1968-
Novković, Ljiljana, 1965-
Sokić-Milutinović, Aleksandra

Opis (srp)

Uvod: Ulcerozni kolitis je zapaljenska bolest creva koja zahvata sluznicu debelogcreva i karakteriše je hronično, rekurentno zapaljenje. Inflamacija u ulceroznomkolitisu značajno povećava rizik od kardiovaskularnih neželjenih događaja.Cilj:Glavni cilj ovog istraživanja je ispitati poveznost biološke iimunosupresivne terapije ulceroznog kolitisa sa markerima oštećenja miokarda prei nakon primene terapije, i korelaciju kliničkih, endoskopskih i patohistološkihparametara pacijenata obolelih od ulceroznog kolitisa sa markerima oštećenjamiokarda.Materijal i metode: U ovoj studiji je uključeno 84 pacijenta sa umereno-teškim iliteškim oblikom ulceroznim kolitisom. Pacijenti su bili podeljeni u tri grupe, naosnovu modaliteta daljeg lečenja: azatioprin, infliksimab, adalimumab. Svimpacijentima smo merili vrednosti srčanih biomarkera (CK, CKMB, proBNP, NTproBNP, troponin) pre terapije, 6 časova nakon terapije, kao i 3 meseca nakon početkaterapije.Rezultati: Pacijenti lečeni anti-TNF terapijom su imali više vrednostinatriuretskih peptida pre započinjanja terapije. U sve tri grupe pacijenata je 6časova nakon primene terapije zabeležen porast natriuretskih peptida, anajizraženiji porast je bio u azatioprin grupi. U dve anti-TNF grupe je nakon 3 mesecalečenja došlo do pada srčanih biomarkera, dok je u azatioprin grupi registrovandalji porast.Zaključak: Najizraženiji kratkoročni i dugoročni neto efekat na natriuretskepeptide je zabeležen u azatioprin grupi. Potrebna su dalja istraživanja obezbednosti i potencijalnoj koristi primene infliksimaba i adalimumaba kodpacijenata sa ulceroznim kolitisom i istovremeno prisutnom srčanom slabošću, uodnosu na azatioprin.

Opis (srp)

-

Opis (eng)

Introduction: Ulcerative colitis is an inflammatory bowel disease that affects the colonicmucosa and is characterized by chronic, recurrent inflammation. The inflammatory process inulcerative colitis significantly increases the risk of cardiovascular adverse events.Aim: The main objective of this study was to examine the association between biological andimmunosuppressive therapy in ulcerative colitis and markers of myocardial injury before andafter treatment, as well as to analyze the correlation between clinical, endoscopic, andhistopathological parameters and myocardial injury markers in patients with ulcerative colitis.Materials and Methods: This study included 84 patients with moderate to severe ulcerativecolitis. Patients were divided into three groups based on the treatment modality: azathioprine,infliximab, and adalimumab. Cardiac biomarkers (CK, CKMB, proBNP, NT-proBNP, andtroponin) were measured in all patients before therapy, 6 hours after therapy, and 3 monthsafter treatment initiation.Results: Patients treated with anti-TNF therapy had higher baseline values of natriureticpeptides prior to treatment initiation. In all three groups, an increase in natriuretic peptidelevels was observed 6 hours after therapy administration, with the most pronounced increaserecorded in the azathioprine group. After 3 months of treatment, a decrease in cardiacbiomarkers was observed in both anti-TNF groups, while a further increase was registered inthe azathioprine group.Conclusion: The most pronounced short- and long-term net increase in natriuretic peptideswas observed in the azathioprine group. Further studies are needed to evaluate the safety andpotential benefits of infliximab and adalimumab therapy in patients with ulcerative colitis andconcomitant heart failure, compared with azathioprine.

Jezik

srpski

Datum

2025

Licenca

Ovo delo je licencirano pod uslovima licence
Creative Commons CC BY 3.0 AT - Creative Commons Autorstvo 3.0 Austria License.

http://creativecommons.org/licenses/by/3.0/at/legalcode